Transcriptomics

Dataset Information

0

Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade


ABSTRACT: Immune checkpoint blockade (ICB) has significantly improved the prognosis of cancer patients, but the majority experience limited benefit, evidencing the need for new therapeutic approaches. Upregulation of sialic acid-containing glycans, termed hypersialylation, is a common feature of cancer-associated glycosylation, driving disease progression and immune escape via the engagement of Siglec-receptors on tumor-infiltrating immune cells. Here, we show that tumor sialylation correlates with distinct immune states and reduced survival in human cancers. The targeted removal of Siglec-ligands in the tumor microenvironment, using an antibody-sialidase conjugate, enhances anti-tumor immunity and halts tumor progression in several mouse tumor models. Using single-cell RNA sequencing, we reveal desialylation mechanistically to repolarize tumor-associated macrophages (TAMs) and identify Siglec-E on TAMs as the main receptor for hypersialylation. Finally, we show genetic and therapeutic desialylation, as well as loss of Siglec-E, to synergize with ICB. Thus, therapeutic desialylation represents a novel immunotherapeutic approach, shaping macrophage phenotypes and augmenting the adaptive anti-tumor immune response.

ORGANISM(S): Mus musculus

PROVIDER: GSE208133 | GEO | 2022/11/24

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2024-05-22 | PXD049188 | Pride
2023-06-02 | GSE224021 | GEO
2023-06-02 | GSE224020 | GEO
2023-06-02 | GSE224024 | GEO
2024-09-19 | GSE268293 | GEO
2024-09-19 | GSE268205 | GEO
2024-01-01 | E-MTAB-12922 | biostudies-arrayexpress
2012-03-31 | E-GEOD-18804 | biostudies-arrayexpress
2019-02-08 | E-MTAB-6885 | biostudies-arrayexpress
2024-10-02 | GSE255711 | GEO